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Abstract
Selective Serotonin Reuptake Inhibitors (SSRIs) are primary treatment options for major 
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the 
metabolism of SSRIs thereby affecting drug efficacy and safety. We summarize evidence from the 
published literature supporting these associations and provide dosing recommendations for 
fluvoxamine, paroxetine, citalopram, escitalopram and sertraline based on CYP2D6 and/or 
CYP2C19 genotype (updates at www.pharmgkb.org).
Keywords
SSRIs; paroxetine; fluoxetine; fluvoxamine; citalopram; escitalopram; sertraline; 
pharmacogenomics; personalized medicine; CPIC
Introduction
Interindividual differences in pharmacokinetic parameter values and treatment outcomes 
with the Selective Serotonin Reuptake Inhibitors (SSRIs) are associated with CYP2D6 or 
CYP2C19 polymorphisms (1). The purpose of this guideline is to provide information to 
allow the interpretation of existing CYP2D6 and/or CYP2C19 genotype tests to guide SSRI 
dosing, particularly focusing on fluvoxamine, paroxetine, citalopram, escitalopram and 
sertraline. Other clinical variables that may influence SSRI therapy as well as genotyping 
cost-effectiveness are beyond the scope of this document. CPIC guidelines are periodically 
updated at http://www.pharmgkb.org.
Focused Literature Review
A systematic literature review focusing on CYP2D6 and CYP2C19 genotype and the 
influence on SSRI therapy was conducted (Supplemental Data).
Genes: CYP2D6 and CYP2C19
CYP2D6 Background
CYP2D6 is highly polymorphic with over 100 known allelic variants and subvariants 
identified (http://www.cypalleles.ki.se/cyp2d6.htm; Supplemental Table S1 and S2). 
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CYP2D6 alleles have been extensively studied in multiple geographically, racially, and 
ethnically diverse groups and significant differences in allele frequencies have been 
observed (Supplemental Table S3). The most commonly reported alleles are categorized into 
functional groups as follows: Normal function (e.g., CYP2D6*1 and *2), decreased function 
(e.g., CYP2D6*9, *10, and *41), and no function (e.g., CYP2D6*3-*6) (2, 3). Because 
CYP2D6 is subject to deletions, gene duplications or multiplications, many clinical 
laboratories also report copy number variations. CYP2D6*5 represents a gene deletion 
whereas gene duplications and multiplications are denoted by “xN” (e.g. CYP2D6*1xN with 
xN representing the number of CYP2D6 gene copies).
CYP2C19 Background
Similar to CYP2D6, the CYP2C19 gene is highly polymorphic with significant differences in 
allele frequencies observed among populations. Over 30 allelic variants and subvariants 
have been identified (http://www.cypalleles.ki.se/cyp2c19.htm; Supplemental Tables S4 and 
S5); however, the majority of patients will carry CYP2C19*1,*2 or *17 alleles. CYP2C19*1 
encodes a normal function enzyme, while CYP2C19*2 is the most common no function 
allele followed by CYP2C19*3. The CYP2C19*17 allele is defined by a variant in the 
promoter region resulting in enhanced gene transcription leading to increased metabolic 
capacity (4). Allele frequencies are provided in Supplemental Table S6.
Genetic Test Interpretation
Clinical laboratories usually test for the more frequently observed CYP2D6 and CYP2C19 
genetic variants and translate the results into star-allele (*) nomenclature. Each star-allele, or 
haplotype, is defined by a specific combination of single-nucleotide polymorphisms and/or 
other genetic variants within the CYP2D6 or CYP2C19 gene locus (2, 5). Supplemental 
Tables S2 and S5 provide a list of CYP2D6 and CYP2C19 alleles and their functional status. 
Genetic test results are reported as the summary of inherited maternal and paternal star-
alleles referred to as a diplotype (e.g., CYP2D6*1/*2 and CYP2C19*1/*1). Supplemental 
Data (Genetic Test Interpretation Section) contains additional information regarding 
CYP2D6 and CYP2C19 genetic test interpretation and phenotype assignment.
Different clinical laboratories may use varying methods to predict phenotype from genotype 
data. Therefore, before any pharmacotherapy modifications are made based upon this 
guideline, it is advisable to predict a patient's phenotype from genotype as described above 
and in the Supplemental Data.
Available Genetic Test Options
Information on commercially available clinical testing options can be found in the 
Supplemental Data, www.pharmgkb.org, or the Genetic Testing Registry (http://
www.ncbi.nlm.nih.gov/gtr/).
Incidental Findings
Some studies have reported an association between CYP2D6 and CYP2C19 genetic variants 
and risk for depression or suicide (Supplemental Data). These associations are poorly 
understood and may be due to either alterations in endogenous physiology or drug 
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metabolism. At present CYP2D6 and CYP2C19 are not considered to be clinically useful 
predictors of depression or suicide risk, nor have they been directly implicated in any 
Mendelian disorders.
Other Considerations
One of the limitations inherent in a genotype-only test is that rare or de novo variants will 
most likely not be included in any commercially available genotyping test. Other important 
considerations pertaining to genetic testing and genetic test interpretation are contained 
within the Supplemental Data.
Drugs: SSRIs
Background
SSRIs are a first line treatment option for major depressive and anxiety disorders, and may 
be used to treat other psychiatric conditions such as obsessive compulsive disorder. 
Although pharmacokinetic properties vary among this drug class, all of the SSRIs 
selectively increase serotonergic activity by decreasing presynaptic serotonin reuptake. The 
more common adverse effects induced by this drug class include central nervous system 
effects (e.g., insomnia, headache), gastrointestinal dysfunction, and sexual dysfunction; 
however, the incidence of side effect occurrence differs with each drug. Serious adverse 
events such as arrhythmias caused by QT prolongation have been associated with SSRIs, 
particularly for individuals prescribed citalopram who are CYP2C19 poor metabolizers (6).
Patients may be predisposed to poor therapeutic outcomes due to CYP2D6 or CYP2C19 
polymorphisms that alter SSRI biotransformation. Paroxetine and fluvoxamine are 
extensively metabolized by CYP2D6 to compounds with little pharmacological activity 
towards serotonin reuptake inhibition (Supplemental Figure S1) (7, 8). Variations in 
CYP2D6 activity may result in lower or greater exposure to these drugs. Fluoxetine 
metabolism is more complex as both CYP2D6 and CYP2C9 convert fluoxetine to 
pharmacologically active norfluoxetine enantiomers (Supplemental Figure S1) (1).
Citalopram is a racemic mixture of R- and S-enantiomers, with the pharmacologically active 
S-enantiomer marketed as escitalopram. Citalopram and escitalopram are extensively 
metabolized by CYP2C19 to compounds that confer less serotonin reuptake inhibition 
(Supplemental Figure S1) (9). Sertraline is metabolized by CYP2D6, CYP2C19 and other 
polymorphic cytochrome P450 enzymes, with pharmacokinetic data suggesting that 
CYP2C19 is the major metabolic pathway (Supplemental Figure S1) (1). Because 
citalopram, escitalopram, and sertraline are extensively catalyzed by CYP2C19, variations in 
CYP2C19 activity may result in altered drug exposure.
Linking genetic variability to variability in drug-related phenotypes
For those diagnosed with major depressive disorder, approximately 50% will fail initial 
SSRI therapy (10). Furthermore, an estimated 25,000 patients per year in the United States 
will seek medical treatment in emergency departments due to adverse events associated with 
antidepressants (11). Utilizing existing pharmacogenetic results to guide SSRI therapy could 
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potentially improve treatment response and decrease the occurrence of adverse events 
(12-14). There is substantial evidence linking CYP2D6 or CYP2C19 genotype to phenotypic 
variability in SSRI pharmacokinetic parameters or treatment outcomes (Supplemental Data). 
The application of a grading system to the evidence linking CYP2D6 and CYP2C19 
genotypes to SSRI pharmacokinetic variability indicates a moderate to high quality of 
evidence for the majority of data (Supplemental Tables S7-S11). This body of evidence, 
rather than randomized clinical trials, provides the basis for SSRI pharmacotherapy 
recommendations in Tables 2 and 3.
Therapeutic Recommendations
The recommendations below and in Tables 2 and 3 apply primarily to actions based on 
genetic tests only; drug interactions and other clinical factors can have a major influence for 
prescribing decisions for SSRIs and should be taken into consideration before initiating drug 
therapy. Based on the current literature, recommendations are made for paroxetine, 
fluvoxamine, citalopram, escitalopram, and sertraline. Considerations regarding fluoxetine 
are discussed below and can be found in the Supplemental Material.
CYP2D6-paroxetine and fluvoxamine dosing recommendations—Table 2 
summarizes the dosing recommendations for paroxetine (Table 2a) and fluvoxamine (Table 
2b) based on CYP2D6 phenotype. Multiple studies have demonstrated that CYP2D6 
ultrarapid metabolizers have low or undetectable paroxetine plasma concentrations when 
compared to CYP2D6 extensive metabolizers (15-18). Those with undetectable paroxetine 
plasma concentrations are likely at risk of therapeutic failure. Low paroxetine plasma 
concentrations may be a risk factor for therapy failure, though the minimal paroxetine 
therapeutic concentration is not well defined (19). Because of the risk for therapy failure due 
to lower drug exposure, an alternative SSRI not extensively metabolized by CYP2D6 should 
be considered. There are insufficient data to calculate an initial paroxetine dose for CYP2D6 
ultrarapid metabolizers. Data are lacking describing the effect of CYP2D6 ultrarapid 
metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for 
fluvoxamine in the context of CYP2D6 ultrarapid metabolizers. It may be reasonable, 
though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the 
lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine 
therapy.
Adjustments to paroxetine or fluvoxamine therapy are not warranted based on CYP2D6 
status for those who are CYP2D6 extensive or intermediate metabolizers. Self-inhibition of 
CYP2D6, and potential phenoconversion may lead to non-linear kinetics at common doses 
in certain genotypes. Although CYP2D6 intermediate metabolizers may be expected to have 
a modest increase in drug exposure and may be more susceptible to CYP2D6 inhibition by 
paroxetine, existing evidence does not support paroxetine or fluvoxamine therapy 
adjustments. In addition, because CYP2D6 diplotypes are inconsistently categorized as 
extensive or intermediate metabolizers, the literature is difficult to evaluate, thus resulting in 
a moderate recommendation classification for intermediate metabolizers.
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When administered similar doses, CYP2D6 poor metabolizers have significantly greater 
drug exposure to paroxetine and fluvoxamine when compared to extensive metabolizers (15, 
20-22). This increase in drug exposure may be a risk factor for drug-induced side effects. 
The US Food and Drug Administration (FDA) states that fluvoxamine should be used 
cautiously inpatients known to have reduced levels of CYP2D6 activity (http://
www.pharmgkb.org/label/PA166104854). To potentially prevent an adverse effect, an 
alternative SSRI not extensively metabolized by CYP2D6 should be considered for poor 
metabolizers. If paroxetine or fluvoxamine is warranted, dose extrapolations based on 
differences in pharmacokinetic parameters between phenotype groups suggest a 50% dose 
reduction of paroxetine and a 30% dose reduction of fluvoxamine (1). However, a 30% 
decrease in fluvoxamine dose may not be feasible given the dosage forms, therefore, 
decreasing the dose of fluvoxamine by 25-50% may help prevent adverse events by limiting 
high drug exposures. Because therapeutic drug monitoring is not common for SSRIs (19), 
limited data are available describing the linearity of the dose-concentration relationship and 
the relation between paroxetine or fluvoxamine concentrations and therapeutic effect and 
tolerability. Therefore, this recommendation is considered to be optional.
Fluoxetine considerations—CYP2D6 converts fluoxetine to S-norfluoxetine while both 
CYP2D6 and CYP2C9 convert fluoxetine to R-norfluoxetine (Supplemental Figure S1). 
Fluoxetine and R/S-norfluoxetine modulate serotonin reuptake, though R-norfluoxetine is 
thought be less pharmacologically active. CYP2D6 poor metabolizers have been 
demonstrated to possess significantly higher fluoxetine plasma concentrations than extensive 
metabolizers (Supplemental Table S10). However, the total sum of fluoxetine plus 
norfluoxetine plasma concentrations may not vary significantly by CYP2D6 phenotypes. 
Little data are available describing how CYP2D6 phenotype status influences the total sum 
of fluoxetine plus norfluoxetine concentrations over time, or if an imbalance between 
fluoxetine and norfluoxetine concentrations caused by CYP2D6 phenotype status affects 
patient outcome or safety. Therefore, no gene-based dosing recommendations are provided 
for fluoxetine. For CYP2D6 ultrarapid and poor metabolizers, it may be reasonable to 
monitor these patients more closely if they are prescribed fluoxetine or to select an 
alternative SSRI not extensively metabolized by CYP2D6 due to conflicting/inconclusive 
data describing how CYP2D6 status influences fluoxetine therapy. It is important to note 
that the prescribing information for fluoxetine states that the drug “should be used with 
caution in patients with congenital long QT syndrome” and that caution is warranted in 
situations that may prolong QT such as “conditions that predispose to increased fluoxetine 
exposure (overdose, hepatic impairment, use of CYP2D6 inhibitors, CYP2D6 poor 
metabolizer status, or use of other highly protein-bound drugs).”
CYP2C19-citalopram, escitalopram and sertraline dosing recommendations—
Table 3 summarizes the dosing recommendations for citalopram and escitalopram based on 
CYP2C19 phenotype. CYP2C19 ultrarapid metabolizers have significantly lower exposure 
to these drugs when compared to extensive metabolizers, and therefore may have an 
increased probability of failing therapy (9, 23, 24). Because there are insufficient data to 
calculate an initial citalopram or escitalopram dose for CYP2C19 ultrarapid metabolizers, an 
alternative SSRI not extensively metabolized by CYP2C19 may be an option if deemed 
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appropriate given other medications and clinical considerations. Drug-drug interactions 
should be considered if selecting an alternative SSRI, such as paroxetine, which inhibits 
CYP2D6. CYP2C19*17 homozygotes have a greater metabolic capacity than CYP2C19*17 
heterozygotes, and may benefit more from alternative therapy (23, 24). Given that there may 
be clinically significant differences among CYP2C19 ultrarapid metabolizers based on 
diplotype (i.e., CYP2C19*1/*17 versus CYP2C19*17/*17), this is a moderate 
recommendation.
Adjustments to citalopram or escitalopram therapy are not warranted based on CYP2C19 
status for those who are CYP2C19 extensive metabolizers. Though CYP2C19 intermediate 
metabolizers may have elevated plasma concentrations, dose extrapolations suggest that 
minimal dose adjustments are warranted for intermediate metabolizers (1). Elevated 
concentrations of these drugs have been observed in poor metabolizers, which may increase 
the risk of adverse drug reactions (24-27). To potentially prevent an adverse effect, an 
alternative SSRI not extensively metabolized by CYP2C19 should be considered. If 
citalopram or escitalopram is warranted an initial dosage decrease of 50% should be 
considered (1). For citalopram, the FDA recommends a 50% dose reduction (or a maximum 
dose of 20 mg/day in adults) for CYP2C19 poor metabolizers due to risk of QT prolongation 
(the FDA recommendation does not apply to escitalopram) (6). Although limited data are 
available describing the relationship between SSRI concentrations and therapeutic effect and 
tolerability, this is a moderate recommendation due to apparent risk for arrhythmias 
combined with the FDA providing specific dose recommendations.
Pharmacokinetic data show reduced oral clearance of sertraline in CYP2C19 poor 
metabolizers (28, 29) but only slightly increased metabolism in ultrarapid metabolizers (28). 
Side effects in CYP2C19 poor metabolizers have also been reported to be more frequent 
than in normal metabolizers (30). Therefore, in CYP2C19 poor metabolizers a dose 
reduction of 50% is recommended or an alternative SSRI not extensively metabolized by 
CYP2C19 should be considered (Table 3). No dose adjustment is recommended for 
CYP2C19 ultrarapid metabolizers; however, if a patient is not responding to adequate 
maintenance doses of sertraline, consider an alternative SSRI not predominantly 
metabolized by CYP2C19. Due to the limited available evidence, this recommendation is 
optional.
Pediatrics—Data describing the relationship between CYP2D6 or CYP2C19 genotype and 
SSRI systemic exposure or steady state plasma concentrations in pediatric patients are 
scarce (Supplemental Data). Because CYP2D6 activity is fully mature by early childhood 
(31), it may be appropriate to extrapolate these recommendations to adolescents or possibly 
younger children with close monitoring. CYP2C19 activity may be increased in children 
relative to adults; therefore, these recommendations should be used with caution in children 
and accompanied by close monitoring. Ultimately, additional research and clinical trials in 
pediatric patients investigating the association between CYP2D6 or CYP2C19 and SSRI 
systemic exposure or treatment outcomes is needed.
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Recommendations for Incidental Findings
Not applicable
Other considerations
Paroxetine and fluoxetine are strong inhibitors of CYP2D6, albeit involving different 
mechanisms (32). Several studies have suggested that CYP2D6 ultrarapid metabolizers may 
not undergo phenoconversion by paroxetine, though some of these studies were short in 
duration and may not be representative of steady-state conditions (15-18). CYP2D6 
extensive and intermediate metabolizers may be more susceptible to paroxetine-induced 
phenoconversion (from extensive/intermediate to intermediate/poor metabolizers due to 
auto-inhibition). Evidence presented in Supplemental Table S8 demonstrates that paroxetine 
pharmacokinetic parameters are significantly different among CYP2D6 poor metabolizers 
when compared to extensive metabolizers. Some of these studies, though, are limited by 
relatively short study periods. (see Supplemental Material for more information).
Many of the SSRIs are substrates for other metabolic enzymes such as CYP1A2, CYP2C9 
and CYP3A4. There is currently no strong evidence supporting gene-based dosing 
recommendations for other cytochrome P450 enzymes that metabolize SSRIs. There is 
increasing evidence that variations in the genes encoding the serotonin transporter (5-HTT, 
SLC6A4) and the serotonin 2A receptor (HTR2A) are associated with SSRI response and 
adverse effects (33). As additional studies are published, gene-based dosing 
recommendation for SLC6A4 and/or HTR2A may be warranted.
The guideline supplement contains examples of clinical decision support (CDS) tools that 
can be used within electronic health records (EHRs) to assist clinicians in applying genetic 
information to patient care for the purpose of drug therapy optimization (See Supplemental 
Material). Clinical implementation resources include cross-references for drug and gene 
names to widely-used terminologies and standardized nomenclature systems (Supplemental 
Tables S12 and S13), work flow diagrams (Supplemental Figures S2 and S3), tables that 
translate genotype test results into a predicted phenotype (Supplemental Tables S14 and 
S15), and example text for documentation in the EHR and point-of-care alerts 
(Supplemental Table S16).
Potential Benefits and Risks for the Patient
Existing CYP2D6 and/or CYP2C19 genotype results may provide the potential benefit of 
identifying patients who are at an increased risk of experiencing adverse drug reactions or 
therapeutic failure. A potential risk is the misinterpretation of genetic test results, as rare or 
novel variants are typically not interrogated. If an individual carries a rare variant, the actual 
phenotype may differ from the predicted phenotype. An individual's CYP2D6 and/or 
CYP2C19 metabolizer status may also depend on other factors including epigenetic 
phenomena, diet, co-morbidities, or comedications (34). Although CYP2D6 and/or 
CYP2C19 genotyping is usually reliable when performed in qualified laboratories, the 
possibility for error in genotyping, contamination, or mislabeling of the sample remains.
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Caveats: Appropriate Use and/or Potential Misuse of Genetic Tests
Patients on a stable and effective dose of an SSRI most likely will not benefit from 
additional dose modifications based on CYP2D6 or CYP2C19 genotype results. Similar to 
all diagnostic tests, genetic tests are one of several pieces of clinical information that should 
be considered before initiating drug therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Assignment of Likely Phenotypes Based on Diplotypes
a. Assignment of CYP2D6 predicted phenotypes
Likely phenotype Activity Score Genotypes Examples of CYP2D6diplotypes
Ultrarapid metabolizer (∼1-2% 
of patients)a
> 2.0 An individual carrying duplications of 
functional alleles
*1/*1xN, *1/*2xN, *2/*2xNb
Extensive metabolizer 
(∼77-92% of patients) 2.0-1.0
c An individual carrying two normal 
function alleles or two decreased 
function alleles or one normal function 
and one no function allele or one normal 
function and one decreased function 
allele
*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, 
*2/*2,*41/*41
Intermediate metabolizer 
(∼2-11% of patients)
0.5 An individual carrying one decreased 
function and one no function allele
*4/*10, *4/*41, *5/*9
Poor metabolizers (∼5-10% of 
patients)
0 An individual carrying only no 
functional alleles
*3/*4, *4/*4, *5/*5, *5/*6
b. Assignment of CYP2C19 predicted phenotypes
Likely phenotype Genotypes Examples of CYP2C19 diplotypes
Ultrarapid metabolizer (∼5-30% of patients)d An individual carrying two increased 
function alleles or one normal function 
allele and one increased function allele
*17/*17, *1/*17
Extensive metabolizer (∼35-50% of patients) An individual carrying two normal 
function alleles
*1/*1
Intermediate metabolizer (∼18-45% of patients) An individual carrying one normal 
function allele or one increased function 
allele and one no function allele
*1/*2, *1/*3, *2/*17e
Poor metabolizer (∼2-15% of patients) An individual carrying two no function 
alleles
*2/*2, *2/*3, *3/*3
aCYP2D6 metabolizer status frequencies are based on data from Caucasians and may differ from other ethnicities. See Supplemental Tables S3 
and S6 note for information on the chances of observing specific diplotypes in different major race/ethnic groups.
bWhere xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for 
additional information on how to translate diplotypes into phenotypes.
c
Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.
dCYP2C19 metabolizer status frequencies are based on average multi-ethnic frequency.
e
The predicted metabolizer phenotype for the *2/*17 genotypes is a provisional classification. The currently available evidence indicates that the 
CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2 (35). See Supplemental Materials for a 
more comprehensive list of predicted metabolizer phenotypes.
Clin Pharmacol Ther. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Hicks et al. Page 13
Table 2
Dosing Recommendations for CYP2D6 and SSRIs
a. Dosing Recommendation for Paroxetine based on CYP2D6 phenotype
Phenotype Implication Therapeutic Recommendation Classification of Recommendationa
CYP2D6 Ultrarapid metabolizer Increased metabolism 
to less active 
compounds when 
compared to extensive 
metabolizers. Lower/
undetectable plasma 
concentrations may 
increase probability of 
pharmacotherapy 
failure.
Select alternative drug not 
predominantly metabolized by 
CYP2D6.b
Strong
CYP2D6 Extensive metabolizer Normal metabolism Initiate therapy with recommended 
starting dose.
Strong
CYP2D6 Intermediate metabolizer Reduced metabolism 
when compared to 
extensive metabolizers. 
Higher plasma 
concentrations may 
increase the probability 
of side effects.
Initiate therapy with recommended 
starting dose.
Moderate
CYP2D6 Poor metabolizer Greatly reduced 
metabolism when 
compared to extensive 
metabolizers. Higher 
plasma concentrations 
may increase the 
probability of side 
effects.
Select alternative drug not 
predominantly metabolized by 
CYP2D6b or if paroxetine use 
warranted, consider a 50% 
reduction of recommended starting 
dose and titrate to response.
Optional
b.Dosing Recommendation for Fluvoxamine based on CYP2D6 phenotype
CYP2D6 Ultrarapid metabolizer No data available for 
CYP2D6 Ultrarapid 
Metabolizers.
No recommendation due to lack of 
evidence.c
Optional
CYP2D6 Extensive metabolizer Normal metabolism Initiate therapy with recommended 
starting dose.
Strong
CYP2D6 Intermediate metabolizer Reduced metabolism 
when compared to 
extensive metabolizers. 
Higher plasma 
concentrations may 
increase the probability 
of side effects.
Initiate therapy with recommended 
starting dose.
Moderate
CYP2D6 Poor metabolizer Greatly reduced 
metabolism when 
compared to extensive 
metabolizers. Higher 
plasma concentrations 
may increase the 
probability of side 
effects.
Consider a 25-50% reductiond of 
recommended starting dose and 
titrate to response or use an 
alternative drug not metabolized by 
CYP2D6.b
Optional
a
Rating scheme described in Supplement.
b
Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an 
alternative therapy.
c
Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are 
provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively 
metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.
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d
Dose extrapolations based on differences in pharmacokinetic parameters between phenotype groups suggest a 30% dose reduction of fluvoxamine 
(1). However, a 30% decrease in dose may not be feasible given the dosage forms, therefore, decreasing the starting dose of fluvoxamine by 
25-50% should be considered.
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Table 3
Dosing Recommendations for CYP2C19 and SSRIs
a. Dosing Recommendations for Citalopram and Escitalopram based on CYP2C19 Phenotype
Phenotype Implication Therapeutic Recommendation Classification of Recommendationa
CYP2C19 Ultrarapid metabolizer Increased metabolism 
when compared to 
extensive 
metabolizers. Lower 
plasma concentrations 
will increase 
probability of 
pharmacotherapy 
failure.
Consider an alternative drug not 
predominantly metabolized by 
CYP2C19.b
Moderate
CYP2C19 Extensive metabolizer Normal metabolism Initiate therapy with recommended 
starting dose.
Strong
CYP2C19 Intermediate metabolizer Reduced metabolism 
when compared to 
extensive 
metabolizers.
Initiate therapy with recommended 
starting dose.
Strong
CYP2C19 Poor metabolizer Greatly reduced 
metabolism when 
compared to extensive 
metabolizers. Higher 
plasma concentrations 
may increase the 
probability of side 
effects.
Consider a 50% reductionc,d of 
recommended starting dose and 
titrate to response or select 
alternative drug not predominantly 
metabolized by CYP2C19.b
Moderate
b. Dosing Recommendations for Sertraline based on CYP2C19 Phenotype
Phenotype Implication Therapeutic Recommendation Classification of Recommendationa
CYP2C19 Ultrarapid metabolizer Increased metabolism 
when compared to 
extensive 
metabolizers.
Initiate therapy with recommended 
starting dose. If patient does not 
respond to recommended 
maintenance dosing, consider 
alternative drug not predominantly 
metabolized by CYP2C19.b
Optional
CYP2C19 Extensive metabolizer Normal metabolism Initiate therapy with recommended 
starting dose.
Strong
CYP2C19 Intermediate metabolizer Reduced metabolism 
when compared to 
extensive 
metabolizers.
Initiate therapy with recommended 
starting dose.
Strong
CYP2C19 Poor metabolizer Greatly reduced 
metabolism when 
compared to extensive 
metabolizers. Higher 
plasma concentrations 
may increase the 
probability of side 
effects.
Consider a 50% reductiond of 
recommended starting dose and 
titrate to response or select 
alternative drug not predominantly 
metabolized by CYP2C19.b
Optional
a
Rating scheme described in Supplemental Materials.
b
Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an 
alternative therapy.
c
Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT 
prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, 
those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.
d
Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (1).
Clin Pharmacol Ther. Author manuscript; available in PMC 2015 August 01.
